Last reviewed · How we verify

ALXN2030 — Competitive Intelligence Brief

ALXN2030 (ALXN2030) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme replacement therapy. Area: Genetics and Rare Diseases.

phase 2 Enzyme replacement therapy alpha-L-iduronidase Genetics and Rare Diseases Small molecule Live · refreshed every 30 min

Target snapshot

ALXN2030 (ALXN2030) — Alexion Pharmaceuticals, Inc.. ALXN2030 is a recombinant human alpha-L-iduronidase enzyme replacement therapy.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ALXN2030 TARGET ALXN2030 Alexion Pharmaceuticals, Inc. phase 2 Enzyme replacement therapy alpha-L-iduronidase
Panzytrat 25.000 FIP-E units of Lipase Panzytrat 25.000 FIP-E units of Lipase Foundation for Liver Research marketed Pancreatic enzyme replacement therapy Triglycerides and dietary lipids
Pegvaliase-Pqpz Pegvaliase-Pqpz University of Missouri-Columbia marketed Enzyme replacement therapy Phenylalanine (substrate); phenylalanine ammonia lyase (active enzyme)
Replagal (agalsidase alfa) Replagal (agalsidase alfa) Shire marketed Enzyme replacement therapy α-galactosidase A (GLA)
Pancrelipase Capsules Pancrelipase Capsules Ohio State University marketed Pancreatic enzyme replacement therapy
Pancreatic Enzyme Pancreatic Enzyme University of Oxford marketed Pancreatic enzyme replacement therapy (PERT)
ALGLUCOSIDASE ALFA (MYOZYME) ALGLUCOSIDASE ALFA (MYOZYME) Genzyme, a Sanofi Company marketed Enzyme replacement therapy Acid alpha-glucosidase (GAA)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme replacement therapy class)

  1. BioMarin Pharmaceutical · 5 drugs in this class
  2. Sanofi · 3 drugs in this class
  3. JCR Pharmaceuticals Co., Ltd. · 2 drugs in this class
  4. Genzyme, a Sanofi Company · 2 drugs in this class
  5. Pfizer Inc. · 1 drug in this class
  6. Shire · 1 drug in this class
  7. Alexion Pharmaceuticals, Inc. · 1 drug in this class
  8. University of Missouri-Columbia · 1 drug in this class
  9. Eurofarma Laboratorios S.A. · 1 drug in this class
  10. ISU Abxis Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALXN2030 — Competitive Intelligence Brief. https://druglandscape.com/ci/alxn2030. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing